Company news
Intellia Therapeutics, Inc. news in 2022
Intellia Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Intellia Therapeutics Announces Proposed Public Offering of Common Stock
November 29, 2022
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
November 29, 2022
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting
November 11, 2022
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022
November 4, 2022
Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress
November 2, 2022
Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting
October 30, 2022
Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2022 Earnings and Company Updates
October 26, 2022
Intellia Therapeutics to Present at October Healthcare Investor Conferences
September 25, 2022
Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)
September 15, 2022
Intellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
September 15, 2022
Intellia Therapeutics Announces Upcoming Investor Event to Present Interim Clinical Data from Ongoing First-in-Human Studies of NTLA-2002 and NTLA-2001 on September 16, 2022
September 7, 2022
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema
August 31, 2022
Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 Bradykinin Symposium
August 22, 2022
Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress
August 3, 2022
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates
July 26, 2022
Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single Dose
June 23, 2022
Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022
June 7, 2022
Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress
May 4, 2022
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference
May 1, 2022
Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors
May 1, 2022
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates
April 27, 2022
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid Leukemia
March 8, 2022
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia
February 28, 2022
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
February 27, 2022
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein
February 27, 2022
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2021 Financial Results and Highlights Recent Company Progress
February 23, 2022
Intellia Therapeutics Enters Lease Agreement to Build Manufacturing Facility for its CRISPR-based Therapies
February 22, 2022
Intellia Therapeutics Announces Two Upcoming Investor Events in February 2022
February 16, 2022
Intellia and ONK Therapeutics Announce Collaboration to Advance Allogeneic CRISPR-Edited NK Cell Therapies for the Treatment of Patients with Cancer
February 14, 2022
Intellia Therapeutics Announces Acquisition of Rewrite Therapeutics
February 2, 2022
Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2022
January 5, 2022
Intellia Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
January 4, 2022
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases
January 4, 2022
Calls in 2022
- Intellia Therapeutics (NASDAQ:NTLA) Q3 2022 Earnings Call
Nov 3, 2022
Transcript - Intellia Therapeutics (NASDAQ:NTLA) Q2 2022 Earnings Call
Aug 4, 2022
Transcript - Intellia Therapeutics (NASDAQ:NTLA) Q1 2022 Earnings Call
May 5, 2022
Transcript - Intellia Therapeutics (NASDAQ:NTLA) Q4 2021 Earnings Call
Feb 24, 2022
Transcript
Decks in 2022
- The International Liver Congress 2022
Conference · 17 slides · Jun 24, 2022
- Technical Presentation (February 2022)
Technical · 38 slides · Feb 28, 2022